Skip to main content

Table 3 Deterministic cost - effectiveness results of Base Case Lifetime Analysis

From: Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece

  Ivabradine + Standard therapy Standard therapy Incremental
Costs    
Total costs (€) 8,655 5,873 2,792
Drug acquisition cost (€) 5,340 2,374 2,966
Hospitalization costs (€) 1,833 1,781 52
HF management costs (€) 1,492 1,754 −262
Health outcomes    
QALYs 4.27 3.99 0.28
LYs 5.86 5.61 0.25
Incremental analysis    
ICER per QALY (€)    9,986
ICER per LY (€)    11,002
  1. ICER: incremental-cost-effectiveness ratio; LY: life-year; QALY: quality-adjusted-life-year.